Drug intelligence / Profile preview

A-ECO red blood cells

Development stage
Phase 1
Lead developer
Velico
Modality
Cell Therapies
Administration
Intravenous
01

Overview

A-ECO red blood cells are a cell therapy product consisting of group A red blood cells that have been enzymatically modified to remove the A-antigen from their surface, effectively converting them into group O (universal donor) cells. Developed by Velico Medical, this technology utilizes specific recombinant alpha-N-acetylgalactosaminidases (glycosidases) to cleave the terminal alpha-1,3-linked N-acetylgalactosamine residue that defines the A blood group. By converting the A-antigen into the H-antigen found on group O cells, the product aims to mitigate the risk of hemolytic transfusion reactions and address shortages in the supply of O-negative and O-positive universal donor blood. Clinical development has focused on evaluating the safety, immunogenicity, and post-transfusion survival of these converted cells in autologous and allogeneic settings.

Other names
Enzyme-converted A-to-O red blood cellsEnzyme-converted A-to-O red cellsECO-RBCEnzyme converted group O red blood cells
02

Targets

A antigen (Blood group A antigen)B antigen (ABO blood group B antigen)

Beyond the preview

Go deeper on A-ECO red blood cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on A-ECO red blood cells.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call